LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotechnology consultancy that provides equity research to clients in medical life-sciences. LifeSci Advisors is a Biotech Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is a Pharmaceutical Investor Relations consultancy that provides equity research to clients in medical life sciences. LifeSci Advisors is an Investor Relations consultancy that provides equity research to clients in Healthcare LifeSci Advisors is an Equity Research consultancy that provides equity research to clients in Pharmaceuticals. LifeSci Advisors is a Corporate Communications consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Healthcare Investor consultancy that provides equity research to clients in Medical Devices. LifeSci Advisors is a Pharmaceutical Investor consultancy that provides equity research to clients in Medical Devices.

Web developed by Bolinger web design

Our Distribution


A.P. Pharma ASCO Abstract Review


« Back to News


A.P. Pharma ASCO Abstract Review

-Highlights Importance of Long-Acting/Extended-Release 5-HT3 Antagonists Like APF530-


Report is Available for Download at: www.lifesciadvisors.com/clients/ap

With this note, we highlight A.P. Pharma’s (OTC BB: APPA.OB) ASCO abstract entitled, “The effect of continuous exposure to serotonin receptor antagonism on delayed emesis: An analysis of 1,535 patients in two randomized clinical trials with granisetron (G), APF530, and palonosetron (palo).” The authors, who include key opinion leaders in cancer supportive care, found that long-acting or extended-release 5-HT3 antagonists, such as APF530, demonstrated better emetic control.

APF530 Provided Better Emetic Control. In this abstract, the authors compared the performance of 5-HT3 antagonists (granisetron, APF530, and palonosetron) in patients from two separate trials with similar populations. The patients in these trials were given highly or moderately emetic chemo and received dexamethasone plus a single administration of a 5-HT3 antagonist. The authors concluded that continuous exposure to a 5-HT3 antagonist as either a long-acting agent (palonosetron) or an extended-release formulation (APF530) provides better emetic control than standard, short-acting granisetron, even with added dexamethasone.

« Back to News

Contact Us   |   About Us   |   Privacy Policy   |   Disclaimer  |   Careers

©2014 LifeSci Advisors, LLC. All Rights Reserved.

email


Web developed by Bolinger web design